Once daily ceftriaxone and gentamicin for the treatment of febrile neutropenia

Archives of Disease in Childhood

Volumn 80, Issue 2, 1999, Pages 125-131

  Tomlinson, Richard J ^a   Ronghe, Milind ^a   Goodbourne, Colin ^b   Price, Christine ^a   Lilleyman, John S ^a   Das, Satya ^b   Saha, Vaskar ^a  

^a ST BARTHOLOMEW S HOSPITAL   (United Kingdom)

^b NONE

Author keywords

Cancer; Ceftriaxone; Febrile neutropenia; Gentamicin; Once daily treatment

Indexed keywords

AMIKACIN; AMPHOTERICIN B; CARBENICILLIN; CEFTAZIDIME; CEFTRIAXONE; CREATININE; GENTAMICIN; PIPERACILLIN; TEICOPLANIN;

ADOLESCENT; ARTICLE; BACTERIUM CULTURE; BLOOD CULTURE; CHILDHOOD CANCER; CREATININE BLOOD LEVEL; DRUG BLOOD LEVEL; FEBRILE NEUTROPENIA; FEMALE; HEARING LOSS; HUMAN; INFANT; LEUKOCYTE COUNT; MALE; PRESCHOOL CHILD; PRIORITY JOURNAL; SCHOOL CHILD; SEPSIS;

EID: 0032988480     PISSN: 00039888     EISSN: 14682044     Source Type: Journal    
DOI: 10.1136/adc.80.2.125     Document Type: Article

References (39)

1. 1 Pizzo PA, Rubin M, Freifeld A, Walsh TJ. The child with cancer and infection. I. Empiric therapy for fever and neutropenia, and preventive strategies. J Pediatr 1991;119:679-94.
2. 2 Klastersky J, Zinner SH, Calandra T, et al. Empiric antimicrobial therapy for febrile granulocytopenic cancer patients: lessons from four EORTC trials. Eur J Cancer Clin Oncol 1988;24(Suppl 1):S35-45.
3. 3 Klastersky J. Therapy for sepsis in neutropenic patients. In: Sande MA, Root RK, eds. Treatment of serious infections in the 1990s. Contemporary issues in infectious diseases. Edinburgh; Churchill Livingstone, 1992:47-63.
4. 4 Smith L, Will AM, Williams RF, Stevens RF. Ceftriaxone vs. azlocillin and netilmicin in the treatment of febrile neutropenic children. J Infect 1990;20:201-6.
5. 5 Pizzo PA, Hathorn JW, Hiemenz J, et al. A randomized trial comparing ceftazidime alone with combination antibiotic therapy in cancer patients with fever and neutropenia. N Engl J Med 1986;315:552-8.
6. 6 Buxbaum A, Georgopoulos A. Postantibiotic effect of ceftriaxone and gentamicin alone and in combination on Klebsiella pneumoniae, Pseudomonas aeruginosa and Streptococcus viridans. Infection 1996;24:459-64.
7. 7 Kapusnik JE, Hackbarth CJ, Chambers HF, Carpenter T, Sande MA, Single, large, daily dosing versus intermittent dosing of tobramycin for treating experimental Pseudomonas pneumonia. J Infect Dis 1988;158:7-12.
8. 8 Hathorn JW, Pizzo PA. Is there a role for monotherapy with beta-lactam antibiotics in the initial empirical management of febrile neutropenic cancer patients? J Antimicrob Chemother 1986;17(Suppl A):41-54.
9. 9 Goldstein FW, Pean Y, Gertner J. Resistance to ceftriaxone and other beta-lactams in bacteria isolated in the community. The Vigil'Roc study group. Antimicrob Agents Chemother 1995;39:2516-19.
10. 10 Fuchs PC, Barry AL, Brown SD. Survey of antimicrobial activity of four commonly used third generation cephalosporins tested against recent bacterial isolates from ten American medical centers, and assessment of disk diffusion test performance. AST surveillance group. Diagn Microbiol Infect Dis 1996;24:213-19.
11. 11 Roosendaal R, Bakker-Woudenberg IA, van den Berghe-van Raffe M, Michel MF. Continuous versus intermittent administration of ceftazidime in experimental Klebsiella pneumoniac pneumonia in normal and leukopenic rats. Antimicrob Agents Chemother 1986;30:403-8.
12. 12 Freeman CD, Nicolau DP, Belliveau PP, Nightingale CH. Once-daily dosing of aminoglycosides: review and recommendations for clinical practice. J Antimicrob Chemother 1997;39:677-86.
13. 13 Daikos GL, Lolans VT, Jackson GG. First-exposure adaptive resistance to aminoglycoside antibiotics in vivo with meaning for optimal clinical use. Antimicrob Agents Chemother 1991;35:117-23.
14. 14 Xiong YQ, Caillon J, Kergueris MF, et al. Adaptive resistance of Pseudomonas aeruginosa induced by aminoglycosides and killing kinetics in a rabbit endocarditis model. Antimicrob Agents Chemother 1997;41:823-6.
15. 15 Verpooten GA, Giuliano RA, Verbist L, Eestermans G, De Broc ME. Once-daily dosing decreases renal accumulation of gentamicin and netilmicin. Clin Pharmacol Ther 1989;45: 22-7.
16. 16 Swan SK. Aminoglycoside nephrotoxicity. Semin Nephrol 1997;17:27-33.
17. 17 Kuharcik CM, Craig AC. New trends in aminoglycoside dosing. Anna Journal 1994;21:447-8.
18. 18 Gilbert DN. Meta-analyses are no longer required for determining the efficacy of single daily dosing of aminoglycosides. Clin Infect Dis 1997;24:816-19.
19. 19 Anonymous. Efficacy and toxicity of single daily doses of amikacin and ceftriaxone versus multiple daily doses of amikacin and ceftazidime for infection in patients with cancer and granulocytopenia. The international antimicrobial therapy cooperative group of the European organization for research and treatment of cancer. Ann Intern Med 1993;119:584-93.
20. 20 Bouffet E, Fuhrmann C, Frappaz D, et al. Once daily antibiotic regimen in paediatric oncology. Arch Dis Child 1994; 70:484-7.
21. 21 Charnas R, Luthi AR, Ruch W. Once daily ceftriaxone plus amikacin vs. three times daily ceftazidime plus amikacin for treatment of febrile neutropenic children with cancer. Writing committee for the international collaboration on antimicrobial treatment of febrile neutropenia in children. Pediatr Infect Dis J 1997;16:346-53.
22. 22 Sahu S, Bapna A, Pai SK, Nair CN, Kurkurc PA, Advani SH. Outpatient antimicrobial protocol for febrile neutropenia. Pediatr Hematol Oncol 1997;14:205-11.
23. 23 Postovsky S, Arush MWB, Kassis E, Elhasid R, Krivoy N. Pharmacokinetic analysis of gentamicin thrice and single daily dosage in pediatric cancer patients. Pediatr Hematol Oncol 1997;14:547-54.
24. 24 Solorzano-Santos F, Miranda-Novales MG, Diaz-Pena R, et al. Amikacin in single daily doses in children with fever. Revista de Investigacion Clinica 1996;48:13-18.
25. 25 Nicolau DP, Freeman CD, Belliveau PP, Nightingale CH, Ross JW, Quintiliani R. Experience with a once-daily aminoglycoside program administered to 2184 adult patients. Antimicrob Agents Chemother 1995;39:650-5.
26. 26 Ho KK, Bryson SM, Thiessen JJ, Greenberg ML, Einarson TR, Leson CL. The effects of age and chemotherapy on gentamicin pharmacokinetics and dosing in pediatric oncology patients. Pharmacotherapy 1995;15:754-64.
27. 27 Phillips JK, Spearing RL, Crome DJ, Davies JM. Gentamicin volumes of distribution in patients with hematologic disorders. N Engl J Med 1988;319:1290.
28. 28 Zeitany RG, el Saghir NS, Santhosh-Kumar CR, Sigmon MA. Increased aminoglycoside dosage requirements in hematologic malignancy. Antimicrob Agents Chemother 1990;34:702-8.
29. 29 Rodvold KA, Danzinger LH, Quinn JP. Single daily doses of aminoglycosides. Lancet 1997;350:1412.
30. 30 Bertino JS Jr, Rotschafer JC. Single daily dose of aminoglycosides - a concept whose time has not yet come. Clin Infect Dis 1997;24:820-3.
31. 31 Karlowsky JA, Zhanel GG, Davidson RJ, Hoban DJ. Postantibiotic effect in Pseudomonas aeruginosa following single and multiple aminoglycoside exposures in vitro. J Antimicrob Chemother 1994;33:937-47.
32. 32 Prins JM, Buller HR, Kuijper EJ, Tange RA, Speelman P. Once versus thrice daily gentamicin in patients with serious infections. Lancet 1993;341:335-9.
33. 33 Chastagner P, Tourniaire B, Perel Y, et al. Prevention of gram-positive infections with teicoplanin during the induction therapy of childhood ALL: results of a prospective randomised trial. Med Pediatr Oncol 1997;29:334.
34. 34 Lucas HP, Attard-Montalto S, Saha V, Bristow A, Kingston JE, Eden OB. Central venous catheter tip position and malfunction in a paediatric oncology unit. Pediatric Surgery International 1996;11:159-63.
35. 35 Saha V, Gupta S, Daum RS. Occurrence and mechanisms of glycopeptide resistance in gram-positive cocci. Infect Agents Dis 1992;1:310-18.
36. 36 Centres for Disease Prevention and Control. Preventing the spread of vancomycin resistance: report from the hospital infection control practices advisory committee. Fed Reg 1994;59:25757-63.
37. 37 British Committee for Standards in Haematology. BCSH guidelines on the insertion and management of central venous lines. Br J Haematol 1997;98:1041-7.
38. 38 Scholz M, Riesinger P, Reinhard H, Muller J, Graf N. Randomised comparison of two different time-based schedules in the treatment of infectious episodes in immunocompromised children. Med Pediatr Oncol 1997; 29:334.
39. 39 Kumana CR, Yuen KY. Parenteral aminoglycoside therapy. Selection, administration and monitoring. Drugs 1994;47: 902-13.